Endocrinology

The new safety labeling changes approved by the FDA address the use of SGLT2 inhibitors prior to surgery.

The new treatment is the first FDA-approved drug to address the overproduction of cortisol in Cushing disease by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis.

The US Food and Drug Administration has released laboratory results of metformin products tested for N-Nitrosodimethylamine.

The US Food and Drug Administration has granted approval to a treatment for thyroid eye disease. It is the first-ever drug to be approved for this indication.

The US Food and Drug Administration has approved the first and only fast-acting mealtime insulin injection that does not have a pre-dosing recommendation for use in children with diabetes.

The FDA has approved Baqsimi nasal powder, the first glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection.

The FDA has approved an oral gonadotropin-releasing hormone antagonist for the treatment of moderate to severe endometriosis pain.

The FDA has approved a new once-weekly, extended-release option for the treatment of adults with type 2 diabetes and uncontrolled blood sugar levels.